These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 11060564)
1. Avoidance of adverse events in restenotic lesions with abciximab? Linnemeier TJ J Invasive Cardiol; 2000 Nov; 12(11):545-6. PubMed ID: 11060564 [No Abstract] [Full Text] [Related]
2. Routine use of abciximab in coronary stenting? Stables RH Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267 [No Abstract] [Full Text] [Related]
3. Glycoprotein IIb/IIIa inhibitors: current indications and future prospects. Reginelli JP; Topol EJ Am J Med; 2000 Aug; 109(3):252-4. PubMed ID: 10974193 [No Abstract] [Full Text] [Related]
4. "IIb or not IIb or maybe IIb?" Is that the question? Or is it "which IIb and to whom?". Brinker JA Catheter Cardiovasc Interv; 2000 Oct; 51(2):145-6. PubMed ID: 11025565 [No Abstract] [Full Text] [Related]
5. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries. Goldschmidt-Clermont PJ J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856 [No Abstract] [Full Text] [Related]
6. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466 [TBL] [Abstract][Full Text] [Related]
7. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven? Lincoff AM; Topol EJ Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004 [No Abstract] [Full Text] [Related]
8. Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Parmar R; Stouffer GA Am J Med Sci; 1997 Jul; 314(1):31-6. PubMed ID: 9216438 [No Abstract] [Full Text] [Related]
9. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials. van de Werf F Eur Heart J; 1996 Mar; 17(3):325-6. PubMed ID: 8737200 [No Abstract] [Full Text] [Related]